NEJM:脑出血急性期强化降压治疗不降低临床死亡率

2013-06-21 NEJM dxy

脑出血的降压治疗一直是学者们争论的焦点,急性期降压对预后的影响尚不明确。来自澳大利亚的Craig S. Anderson等医生研究了脑出血强化降压与临床预后的关系,发表在2013年6月20日的NEJM杂志上。结果显示:脑出血强化降压不改善死亡率及重度残疾率,但改善脑出血后改良Rankin评分。 该研究纳入2839例自发性脑出血伴收缩压增高的患者,入组时间均在起病6小时内,随机分为两组,一组为强化

脑出血的降压治疗一直是学者们争论的焦点,急性期降压对预后的影响尚不明确。来自澳大利亚的Craig S. Anderson等医生研究了脑出血强化降压与临床预后的关系,发表在2013年6月20日的NEJM杂志上。结果显示:脑出血强化降压不改善死亡率及重度残疾率,但改善脑出血后改良Rankin评分。

该研究纳入2839例自发性脑出血伴收缩压增高的患者,入组时间均在起病6小时内,随机分为两组,一组为强化降压组(1小时内目标收缩压为<140 mm Hg),另一组为指南推荐治疗组(目标收缩压为<180 mm Hg),药物选择由临床医师选择。主要终点事件为死亡或重度残疾,重度残疾定义为发病90天后改良的Rankin评分为3到6分,改良的Rankin评分0分表现无症状,5分显示重度残疾,6分代表死亡。采用预先设定的顺序分析方法分析改良的Rankin评分。同时,分析两组患者的严重不良反应发生率。

在有记载主要终点事件的2794例患者中,1382例患者接受强化降压治疗,其中719例(52.0%)出现主要终点事件;1412例接受指南推荐治疗,其中785例(55.6%)出现主要终点事件,强化降压组的优势比为0.87,95%可信区间[CI]为0.75到1.01,P=0.06。顺序分析显示强化降压组明显降低改良Rankin评分,较重残疾的优势比为0.87,95%可信区间CI为0.77到1.00,P=0.04。强化降压组死亡率为11.9%,指南推荐治疗组为12.0%。非致命性不良反应两组发生率分别为23.3%和23.6%。

在脑出血患者中,强化降压并没有明显降低死亡或重度残疾等主要终点事件的发生率。改良Rankin评分的有序分析显示强化降压可改善功能预后。

Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage.
BACKGROUND
Whether rapid lowering of elevated blood pressure would improve the outcome in patients with intracerebral hemorrhage is not known.
METHODS
We randomly assigned 2839 patients who had had a spontaneous intracerebral hemorrhage within the previous 6 hours and who had elevated systolic blood pressure to receive intensive treatment to lower their blood pressure (with a target systolic level of <140 mm Hg within 1 hour) or guideline-recommended treatment (with a target systolic level of <180 mm Hg) with the use of agents of the physician's choosing. The primary outcome was death or major disability, which was defined as a score of 3 to 6 on the modified Rankin scale (in which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death) at 90 days. A prespecified ordinal analysis of the modified Rankin score was also performed. The rate of serious adverse events was compared between the two groups.
RESULTS
Among the 2794 participants for whom the primary outcome could be determined, 719 of 1382 participants (52.0%) receiving intensive treatment, as compared with 785 of 1412 (55.6%) receiving guideline-recommended treatment, had a primary outcome event (odds ratio with intensive treatment, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P=0.06). The ordinal analysis showed significantly lower modified Rankin scores with intensive treatment (odds ratio for greater disability, 0.87; 95% CI, 0.77 to 1.00; P=0.04). Mortality was 11.9% in the group receiving intensive treatment and 12.0% in the group receiving guideline-recommended treatment. Nonfatal serious adverse events occurred in 23.3% and 23.6% of the patients in the two groups, respectively.
CONCLUSIONS
In patients with intracerebral hemorrhage, intensive lowering of blood pressure did not result in a significant reduction in the rate of the primary outcome of death or severe disability. An ordinal analysis of modified Rankin scores indicated improved functional outcomes with intensive lowering of blood pressure. (Funded by the National Health and Medical Research Council of Australia; INTERACT2 ClinicalTrials.gov number, NCT00716079.).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678248, encodeId=b01916e8248b0, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Tue Jun 25 22:33:00 CST 2013, time=2013-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291795, encodeId=705f1291e95fe, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360833, encodeId=ca4613608332a, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419058, encodeId=17c514190584a, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
    2013-06-25 feifers
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678248, encodeId=b01916e8248b0, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Tue Jun 25 22:33:00 CST 2013, time=2013-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291795, encodeId=705f1291e95fe, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360833, encodeId=ca4613608332a, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419058, encodeId=17c514190584a, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678248, encodeId=b01916e8248b0, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Tue Jun 25 22:33:00 CST 2013, time=2013-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291795, encodeId=705f1291e95fe, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360833, encodeId=ca4613608332a, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419058, encodeId=17c514190584a, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678248, encodeId=b01916e8248b0, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Tue Jun 25 22:33:00 CST 2013, time=2013-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291795, encodeId=705f1291e95fe, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360833, encodeId=ca4613608332a, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419058, encodeId=17c514190584a, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Sun Jun 23 06:33:00 CST 2013, time=2013-06-23, status=1, ipAttribution=)]

相关资讯

Stroke:胆固醇水平与脑出血风险呈负相关

各种胆固醇的水平与脑出血的风险相关并不一致,各种胆固醇的水平与脑出血之间的关系如何尚不清楚。为此,我国第二军医大附属长征医院神经外科的黄承光教授等人进行了一项研究,研究结果在线发表在2013年5月23日的Stroke杂志上。研究结果显示:总胆固醇水平与脑出血风险呈负相关,较高的低密度脂蛋白水平可能与较低的脑出血风险相关,高密度脂蛋白可能与脑出血风险呈正相关。 该研究是一项系统回顾及meta分析。

Stroke:含咖啡因药与出血性卒中危险增加相关

  韩国一项研究表明,应用含有咖啡因的药物(CCM)与出血性卒中(HS)危险增加相关,包括蛛网膜下腔出血和脑出血。论文6月6日在线发表于《卒中》(Stroke)杂志。   该多中心病例对照研究共纳入940例年龄在30—84之间无卒中病史的非创伤性急性HS患者,以与之年龄和性别相匹配的940社区居民和住院者作为对照组。获取各组患者卒中首发时间及此时间之前的14天患者的药物应用信息。以首发卒中前或卒

Stroke:吸烟增加中国老人出血性卒中死亡率

出血性卒中在非西方人群中更多见,通常与其他的心血管疾病没有同样的危险因素。吸烟与出血性卒中亚型之间的相关性尚未确定。为此,香港大学社区医学与公共卫生系的Lin Xu博士等人进行了一项研究,在香港的大样本老年人队列中检验吸烟与出血性卒中(包括脑出血与蛛网膜下腔出血)的相关性,研究结果在线发表在2013年5月30日的Stroke杂志上。研究结果显示:吸烟与出血性卒中死亡率强相关,特别是蛛网膜下腔出血。

Stroke:糖化血红蛋白A1或可有效预测卒中溶栓的出血风险

症状性颅内出血(sICH)是静脉溶栓最急且较严重的并发症,而往往很难预测出血的风险。来自德国的A. Rocco等医生评价了急性卒中溶栓后出血的预测情况,在线发表在2013年5月28日的stroke杂志上。该研究的目的是评估糖化血红蛋白A1(HbA1c)对症状性脑出血的预测价值。研究显示:糖化血红蛋白或可有效预测卒中溶栓的出血风险。 在一项回顾性单中心研究中,共纳入1112例连续登记的静脉溶栓患者

Stroke:脑出血急性期进一步强化降压治疗或利于临床预后

急性脑出血患者的降压治疗时常规急性期处理的一部分。然而,降压治疗与临床预后的关系尚不明确。来自日本的Yuki Sakamoto等人研究了这方面的问题,在线发表在2013年5月23日的stroke杂志上,研究结果显示:脑出血急性期进一步强化降压治疗或利于临床预后。 该研究纳入脑出血超急性期(发病3小时内)初始收缩压超过180 mm Hg的患者。所有患者接受静脉降压治疗,基于预订的目标,血压降至1

Circulation:卒中和脑出血对感染性心内膜炎有负面影响

  西班牙一项研究表明,中重度缺血性卒中和脑出血对感染性心内膜炎(IE)转归具有显著负面影响。研究进一步提示了早期适当地抗菌治疗的重要性,且应考虑暂时中断抗凝治疗。论文于5月6日在线发表于《循环》(Circulation)。   此项研究共纳入1345例次左侧IE发作,并对前瞻性采集的资料进行了回顾性分析。利用Cox回归模型分析神经系统并发症和相关死亡的预测变量。   结果显示,共有340例患